About Vaishali Pharma Limited
Data last updated: 14 July 2026
Vaishali Pharma Limited is a public limited company based in Mumbai, Maharashtra, India. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 25 April 2008, the company has been in operation for over 18 years.
Registered with ROC Mumbai under CIN U52310MH2008PTC181632. Listed on NSE: VAISHALI.
Capital: an authorised share capital of ₹27 Cr and a paid-up capital of ₹27 Cr. Formerly known as Vaishali Pharma Private Limited. It is led by directors including Atul Arvind Vasani and Jagruti Atul Vasani.
Last AGM: 22 September 2025. Financial statements filed for year ended 31 March 2025. Office: Mumbai, Maharashtra.
As per NSE-filed consolidated financials for FY 2026, the company reported a revenue of ₹108.77 Cr. The net worth stands at ₹69.12 Cr. Total assets are valued at ₹123.39 Cr.
The company has a workforce of approximately 15 employees as per the latest available data.
The company is associated with 1 brand - Vaishali Pharma. As per MCA filings, the company has open charges of ₹21.33 Cr and satisfied charges of ₹15.12 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website vaishalipharma.com.
-
EmailLocked
-
TelephoneLocked
-
WebsiteLocked
-
Social Media
-
Registered Address706 To 709 7Th Fl Aravali Busines Center R. C. Patel Road Off Sodawala Lane Bor, Ivali West, Mumbai, Maharashtra, India – 400092
-
IndustryPharma, Drug Formulation & Development
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
CIN History of Vaishali Pharma Limited
Vaishali Pharma Limited has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L52310MH2008PLC181632, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L52310MH2008PLC181632 | Current |
| U52310MH2008PTC181632 | Previous |
| U52310MH2008PLC181632 | Previous |
Associated Brands with Vaishali Pharma Limited
Vaishali Pharma Limited operates one associated brand: Vaishali Pharma. These brands represent Vaishali Pharma Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Finished formulations, APIs, and intermediates are manufactured. | vaishalipharma.com |
Competitors & Alternatives of Vaishali Pharma Limited
Brands and companies operating in the same space as Vaishali Pharma Limited include Concord Biotech, BDR Pharmaceuticals Internationals, Almac Group and 7 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
Concord Biotech
|
APIs and enzymes are manufactured through fermentation by the CDMO. | Ahmedabad, India, India | 2000 |
BDR Pharmaceuticals Internationals
|
APIs and finished products are developed and manufactured. | Mumbai, India, India | 2003 |
Almac Group
|
Integrated CDMO services for biopharma R&D and manufacturing are offered. | Craigavon, United Kingdom, United Kingdom | 2001 |
Indoco Remedies
|
APIs manufacturing and formulation services are provided in therapeutic segments. | Mumbai, India, India | 1947 |
Pharmaceutics International
|
Pharmaceutical dosage forms are manufactured by this CDMO. | Hunt Valley, United States, United States | 1994 |
Aurobindo Pharma
|
Generic biocatalytic solutions are provided for pharmaceutical applications. | Hyderabad, India, India | 1986 |
Seqens
|
Contract manufacturing services for small molecules and peptides are provided. | Ecully, France, France | 2003 |
Asymchem
|
APIs and peptides are developed and manufactured by Asymchem. | Morrisville, United States, United States | 1995 |
Aptuit
|
Contract research and development services for small molecules are offered. | Greenwich, United States, United States | 2004 |
Continuus Pharma
|
MIT-Novartis spinoff offering continuous manufacturing solutions to remove the proverbial wall between API and FDF manufacturing in small molecule development | Woburn, United States, United States | 2012 |
Business Activity of Vaishali Pharma Limited
Vaishali Pharma Limited is engaged in the principal business activity of trade, with detailed activities including wholesale trading.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading | Locked |
Business activity turnover details for Vaishali Pharma Limited
Turnover contribution percentages and historical activity changes require an active report plan.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Auditor Details of Vaishali Pharma Limited
Vaishali Pharma Limited is audited by RAMAN S. SHAH & ASSOCIATES (ICAI peer reviewed, certificate valid till 2026-12-31) for the financial year 2026, as reported in its NSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.
| Name | Financial year | Audit opinion |
|---|---|---|
| RAMAN S. SHAH & ASSOCIATES (ICAI peer reviewed, certificate valid till 2026-12-31) | FY 2026 | Declaration of unmodified opinion |
Board of Directors of Vaishali Pharma Limited
Vaishali Pharma Limited is currently managed by 6 directors, with 8 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Atul Arvind Vasani | Managing Director | 25 Apr 2008 | 18 Years 2 Months | Current |
| Jagruti Atul Vasani | Whole-Time Director | 12 Nov 2009 | 16 Years 8 Months | Current |
| Dewansh Ajay Vasani | Director | 26 Apr 2018 | 8 Years 2 Months | Current |
| Manish Bhagwandas Ved | Director | 31 Dec 2019 | 6 Years 6 Months | Current |
| Pratik Vikram Jakhelia | Director | 10 Jul 2021 | 5 Years 0 Months | Current |
|
Bhaveshkumar Popatlal Upadhyay
Also directs:
Magnet Media Solutions Llp, Ei Gennext Consultus Llp, Agricon Nutritech Limited and 1 more
|
Director | 28 Jan 2025 | 1 Years 5 Months | Current |
Financials of Vaishali Pharma Limited FY 2026 filings available
Vaishali Pharma Limited reported revenue of ₹108.77 Cr for FY 2026.
| Metrics | FY 2026 |
|---|---|
| Revenue from Operations | ₹108.77 Cr |
| Other Income | ₹3.84 Cr |
| Total Income | ₹112.61 Cr |
| Cost of Materials Consumed | ₹0 |
| Purchases of Stock-in-Trade | ₹93.71 Cr |
| Changes in Inventories | ₹1.41 Cr |
| Employee Benefit Expense | ₹2.91 Cr |
| Finance Costs | ₹1.96 Cr |
| Depreciation & Amortisation | ₹59.99 Lakh |
| Other Expenses | ₹6.62 Cr |
| Total Expenses | ₹107.22 Cr |
| Profit Before Exceptional Items & Tax | ₹5.39 Cr |
| Exceptional Items | ₹0 |
| Profit Before Tax | ₹5.39 Cr |
| Total Tax Expense | ₹1.36 Cr |
| Net Profit | ₹4.16 Cr |
| Other Comprehensive Income | ₹3.45 Lakh |
| Total Comprehensive Income | ₹4.2 Cr |
| EBITDA (computed) | ₹7.95 Cr |
| Basic EPS | ₹0.32 |
| Diluted EPS | ₹0.32 |
| Metrics | FY 2026 |
|---|---|
| Total Assets | ₹123.39 Cr |
| Non-current Assets | ₹10.43 Cr |
| Current Assets | ₹112.96 Cr |
| Property, Plant & Equipment | ₹89.89 Lakh |
| Inventories | ₹3.4 Cr |
| Trade Receivables | ₹50.77 Cr |
| Cash & Equivalents | ₹1.11 Cr |
| Equity (Net Worth) | ₹69.12 Cr |
| Equity Share Capital | ₹26.09 Cr |
| Borrowings (Non-current) | ₹5.69 Cr |
| Borrowings (Current) | ₹12.84 Cr |
| Total Debt (computed) | ₹18.53 Cr |
| Current Liabilities | ₹48.3 Cr |
| Total Liabilities | ₹54.27 Cr |
| Metrics |
|---|
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 |
|---|---|---|---|
| Revenue from Operations | ₹26.93 Cr | ₹24.65 Cr | ₹33.45 Cr |
| Other Income | ₹1.26 Cr | ₹89.17 Lakh | ₹83.9 Lakh |
| Total Income | ₹28.19 Cr | ₹25.54 Cr | ₹34.29 Cr |
| Cost of Materials Consumed | ₹0 | ₹0 | ₹0 |
| Purchases of Stock-in-Trade | ₹27.33 Cr | ₹19.57 Cr | ₹28 Cr |
| Changes in Inventories | -₹2.87 Cr | ₹1.37 Cr | ₹1.69 Cr |
| Employee Benefit Expense | ₹77.58 Lakh | ₹72.24 Lakh | ₹63.15 Lakh |
| Finance Costs | ₹72.08 Lakh | ₹50.82 Lakh | ₹40.09 Lakh |
| Depreciation & Amortisation | ₹15.89 Lakh | ₹12.67 Lakh | ₹17.22 Lakh |
| Other Expenses | ₹1.9 Cr | ₹1.43 Cr | ₹1.73 Cr |
| Total Expenses | ₹28.01 Cr | ₹23.73 Cr | ₹32.63 Cr |
| Profit Before Exceptional Items & Tax | ₹17.96 Lakh | ₹1.82 Cr | ₹1.66 Cr |
| Exceptional Items | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹17.96 Lakh | ₹1.82 Cr | ₹1.66 Cr |
| Total Tax Expense | -₹8.69 Lakh | ₹51.48 Lakh | ₹47.15 Lakh |
| Net Profit | ₹38.11 Lakh | ₹1.32 Cr | ₹1.19 Cr |
| Other Comprehensive Income | ₹3.16 Lakh | ₹0 | ₹0 |
| Total Comprehensive Income | ₹41.27 Lakh | ₹1.32 Cr | ₹1.19 Cr |
| EBITDA (computed) | ₹1.06 Cr | ₹2.45 Cr | ₹2.23 Cr |
| Basic EPS | ₹0.03 | ₹0.10 | ₹0.09 |
| Diluted EPS | ₹0.03 | ₹0.10 | ₹0.09 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue from Operations | ₹108.77 Cr | ₹99.03 Cr | ₹86.28 Cr | ₹69.66 Cr | ₹53.77 Cr | ₹60.09 Cr |
| Other Income | ₹3.84 Cr | ₹3.21 Cr | ₹2.03 Cr | ₹2.23 Cr | ₹1.81 Cr | ₹2.17 Cr |
| Total Income | ₹112.61 Cr | ₹102.23 Cr | ₹88.31 Cr | ₹71.89 Cr | ₹55.58 Cr | ₹62.26 Cr |
| Cost of Materials Consumed | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Purchases of Stock-in-Trade | ₹93.71 Cr | ₹90.1 Cr | ₹71.75 Cr | ₹57.1 Cr | ₹45.86 Cr | ₹50.99 Cr |
| Changes in Inventories | ₹1.41 Cr | -₹4.43 Cr | ₹2.67 Cr | -₹2.42 Cr | ₹29.19 Lakh | ₹10.12 Lakh |
| Employee Benefit Expense | ₹2.91 Cr | ₹2.58 Cr | ₹2.32 Cr | ₹2.08 Cr | ₹1.85 Cr | ₹1.93 Cr |
| Finance Costs | ₹1.96 Cr | ₹1.58 Cr | ₹1.74 Cr | ₹2.01 Cr | ₹2.61 Cr | ₹2.48 Cr |
| Depreciation & Amortisation | ₹59.99 Lakh | ₹48.67 Lakh | ₹50.81 Lakh | ₹50.44 Lakh | ₹42.69 Lakh | ₹43.85 Lakh |
| Other Expenses | ₹6.62 Cr | ₹10.68 Cr | ₹8.4 Cr | ₹3.77 Cr | ₹3.14 Cr | ₹6.24 Cr |
| Total Expenses | ₹107.22 Cr | ₹101.01 Cr | ₹87.39 Cr | ₹63.05 Cr | ₹54.18 Cr | ₹62.18 Cr |
| Profit Before Exceptional Items & Tax | ₹5.39 Cr | ₹1.23 Cr | ₹92.61 Lakh | ₹8.85 Cr | ₹1.4 Cr | ₹7.91 Lakh |
| Exceptional Items | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹5.39 Cr | ₹1.23 Cr | ₹92.61 Lakh | ₹8.85 Cr | ₹1.4 Cr | ₹7.91 Lakh |
| Total Tax Expense | ₹1.36 Cr | ₹40.84 Lakh | ₹20.72 Lakh | ₹2.24 Cr | ₹35.82 Lakh | ₹4.63 Lakh |
| Net Profit | ₹4.03 Cr | ₹81.73 Lakh | ₹71.89 Lakh | ₹6.6 Cr | ₹1.05 Cr | ₹3.28 Lakh |
| attributable to Owners | - | - | - | - | ₹0 | - |
| attributable to NCI | - | - | - | - | ₹0 | - |
| Other Comprehensive Income | ₹3.76 Lakh | ₹29,000 | ₹2.17 Lakh | ₹3.89 Lakh | -₹91,000 | -₹1.23 Lakh |
| Total Comprehensive Income | ₹4.07 Cr | ₹82.02 Lakh | ₹74.06 Lakh | ₹6.64 Cr | ₹1.04 Cr | ₹2.05 Lakh |
| EBITDA (computed) | ₹7.95 Cr | ₹3.3 Cr | ₹3.17 Cr | ₹11.36 Cr | ₹4.44 Cr | ₹3 Cr |
| Basic EPS | ₹0.31 | ₹0.31 | ₹0.67 | ₹6.26 | ₹0.99 | ₹0.03 |
| Diluted EPS | ₹0.31 | ₹0.31 | ₹0.64 | ₹5.91 | ₹0.99 | ₹0.03 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Total Assets | ₹123.26 Cr | ₹109.84 Cr | ₹79.96 Cr | ₹78.91 Cr |
| Non-current Assets | ₹10.3 Cr | ₹5.36 Cr | ₹5.44 Cr | ₹6.23 Cr |
| Current Assets | ₹112.96 Cr | ₹104.48 Cr | ₹74.52 Cr | ₹72.68 Cr |
| Property, Plant & Equipment | ₹89.89 Lakh | ₹64.95 Lakh | ₹1.46 Cr | ₹1.8 Cr |
| Inventories | ₹3.4 Cr | ₹4.81 Cr | ₹37.97 Lakh | ₹3.05 Cr |
| Trade Receivables | ₹50.77 Cr | ₹46.72 Cr | ₹49.43 Cr | ₹53.62 Cr |
| Cash & Equivalents | ₹1.11 Cr | ₹1.71 Cr | ₹1.46 Cr | ₹52.91 Lakh |
| Equity (Net Worth) | ₹68.99 Cr | ₹64.92 Cr | ₹42.84 Cr | ₹40.53 Cr |
| Equity Share Capital | ₹26.09 Cr | ₹26.09 Cr | ₹10.72 Cr | ₹10.55 Cr |
| Borrowings (Non-current) | ₹5.69 Cr | ₹4.2 Cr | ₹3.6 Cr | ₹5.23 Cr |
| Borrowings (Current) | ₹12.84 Cr | ₹7.46 Cr | ₹9.01 Cr | ₹8.44 Cr |
| Total Debt (computed) | ₹18.53 Cr | ₹11.66 Cr | ₹12.61 Cr | ₹13.66 Cr |
| Current Liabilities | ₹48.3 Cr | ₹40.05 Cr | ₹33.08 Cr | ₹32.08 Cr |
| Total Liabilities | ₹54.27 Cr | ₹44.93 Cr | ₹37.12 Cr | ₹38.38 Cr |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Operating Cash Flow | ₹30.57 Lakh | -₹18.04 Cr | ₹80.67 Lakh | ₹1.08 Cr |
| Investing Cash Flow | -₹5.33 Cr | -₹18.81 Lakh | ₹1.2 Cr | ₹28.21 Lakh |
| Financing Cash Flow | ₹4.61 Cr | ₹18.49 Cr | -₹1.42 Cr | -₹1.73 Cr |
| Capital Expenditure | ₹45.9 Lakh | ₹30.46 Lakh | ₹0 | ₹0 |
| Free Cash Flow (computed) | -₹15.33 Lakh | -₹18.34 Cr | ₹80.67 Lakh | ₹1.08 Cr |
| Dividends Paid | ₹0 | ₹0 | ₹0 | ₹0 |
| Net Change in Cash | -₹41.29 Lakh | ₹26.47 Lakh | ₹59.36 Lakh | -₹37.06 Lakh |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24 | Q3 FY24 | Q2 FY24 | Q1 FY24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹26.93 Cr | ₹24.65 Cr | ₹33.45 Cr | ₹23.75 Cr | ₹32.25 Cr | ₹27.91 Cr | ₹20.79 Cr | ₹18.08 Cr | ₹32.4 Cr | ₹27.9 Cr | ₹12.57 Cr | ₹13.42 Cr |
| Other Income | ₹1.26 Cr | ₹89.17 Lakh | ₹83.9 Lakh | ₹84.25 Lakh | ₹1 Cr | ₹1.07 Cr | ₹70.92 Lakh | ₹42.45 Lakh | ₹90.54 Lakh | ₹46.97 Lakh | ₹29.78 Lakh | ₹36.07 Lakh |
| Total Income | ₹28.19 Cr | ₹25.54 Cr | ₹34.29 Cr | ₹24.59 Cr | ₹33.25 Cr | ₹28.98 Cr | ₹21.49 Cr | ₹18.5 Cr | ₹33.3 Cr | ₹28.37 Cr | ₹12.86 Cr | ₹13.78 Cr |
| Cost of Materials Consumed | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Purchases of Stock-in-Trade | ₹27.33 Cr | ₹19.57 Cr | ₹28 Cr | ₹18.81 Cr | ₹31.29 Cr | ₹26 Cr | ₹18.31 Cr | ₹14.5 Cr | ₹31.82 Cr | ₹23.82 Cr | ₹7.96 Cr | ₹8.14 Cr |
| Changes in Inventories | -₹2.87 Cr | ₹1.37 Cr | ₹1.69 Cr | ₹1.22 Cr | -₹64.85 Lakh | -₹2.27 Cr | -₹1.51 Cr | -₹57,000 | ₹49.18 Lakh | ₹10.58 Lakh | ₹28.81 Lakh | ₹1.78 Cr |
| Employee Benefit Expense | ₹77.58 Lakh | ₹72.24 Lakh | ₹63.15 Lakh | ₹78.43 Lakh | ₹73.93 Lakh | ₹63.04 Lakh | ₹62.29 Lakh | ₹58.68 Lakh | ₹63.14 Lakh | ₹56.47 Lakh | ₹58.84 Lakh | ₹53.93 Lakh |
| Finance Costs | ₹72.08 Lakh | ₹50.82 Lakh | ₹40.09 Lakh | ₹33.25 Lakh | ₹44.2 Lakh | ₹38.44 Lakh | ₹37.75 Lakh | ₹37.91 Lakh | ₹40.06 Lakh | ₹43.48 Lakh | ₹47.11 Lakh | ₹43.04 Lakh |
| Depreciation & Amortisation | ₹15.89 Lakh | ₹12.67 Lakh | ₹17.22 Lakh | ₹14.2 Lakh | ₹12.29 Lakh | ₹12.28 Lakh | ₹12.18 Lakh | ₹11.92 Lakh | ₹14.05 Lakh | ₹12.42 Lakh | ₹12.36 Lakh | ₹11.98 Lakh |
| Other Expenses | ₹1.9 Cr | ₹1.43 Cr | ₹1.73 Cr | ₹1.56 Cr | ₹6.9 Cr | ₹2.18 Cr | ₹93.98 Lakh | ₹65.72 Lakh | ₹6.23 Cr | ₹44.98 Lakh | ₹1.07 Cr | ₹65.19 Lakh |
| Total Expenses | ₹28.01 Cr | ₹23.73 Cr | ₹32.63 Cr | ₹22.85 Cr | ₹38.85 Cr | ₹27.05 Cr | ₹18.86 Cr | ₹16.23 Cr | ₹39.72 Cr | ₹25.5 Cr | ₹10.5 Cr | ₹11.66 Cr |
| Profit Before Exceptional Items & Tax | ₹17.96 Lakh | ₹1.82 Cr | ₹1.66 Cr | ₹1.74 Cr | -₹5.6 Cr | ₹1.93 Cr | ₹2.63 Cr | ₹2.27 Cr | -₹6.42 Cr | ₹2.86 Cr | ₹2.36 Cr | ₹2.12 Cr |
| Exceptional Items | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹17.96 Lakh | ₹1.82 Cr | ₹1.66 Cr | ₹1.74 Cr | -₹5.6 Cr | ₹1.93 Cr | ₹2.63 Cr | ₹2.27 Cr | -₹6.42 Cr | ₹2.86 Cr | ₹2.36 Cr | ₹2.12 Cr |
| Total Tax Expense | -₹8.69 Lakh | ₹51.48 Lakh | ₹47.15 Lakh | ₹45.6 Lakh | -₹1.31 Cr | ₹48.5 Lakh | ₹66.17 Lakh | ₹57.12 Lakh | -₹1.73 Cr | ₹75.16 Lakh | ₹65.63 Lakh | ₹53.32 Lakh |
| Net Profit | ₹26.65 Lakh | ₹1.3 Cr | ₹1.18 Cr | ₹1.28 Cr | -₹4.29 Cr | ₹1.44 Cr | ₹1.97 Cr | ₹1.7 Cr | -₹4.68 Cr | ₹2.11 Cr | ₹1.7 Cr | ₹1.59 Cr |
| Other Comprehensive Income | ₹3.47 Lakh | ₹0 | ₹0 | ₹0 | ₹29,000 | ₹0 | ₹0 | ₹0 | ₹2.17 Lakh | ₹0 | ₹0 | ₹0 |
| Total Comprehensive Income | ₹30.12 Lakh | ₹1.3 Cr | ₹1.18 Cr | ₹1.28 Cr | -₹4.29 Cr | ₹1.44 Cr | ₹1.97 Cr | ₹1.7 Cr | -₹4.66 Cr | ₹2.11 Cr | ₹1.7 Cr | ₹1.59 Cr |
| EBITDA (computed) | ₹1.06 Cr | ₹2.45 Cr | ₹2.23 Cr | ₹2.21 Cr | -₹5.04 Cr | ₹2.43 Cr | ₹3.13 Cr | ₹2.77 Cr | -₹5.88 Cr | ₹3.42 Cr | ₹2.95 Cr | ₹2.67 Cr |
| Basic EPS | ₹0.02 | ₹0.10 | ₹-0.49 | ₹0.10 | ₹-3.17 | ₹0.98 | ₹1.51 | ₹1.48 | ₹-4.37 | ₹1.99 | ₹1.61 | ₹1.50 |
| Diluted EPS | ₹0.02 | ₹0.10 | ₹-0.49 | ₹0.10 | ₹-3.17 | ₹0.98 | ₹1.51 | ₹1.38 | ₹-4.17 | ₹1.89 | ₹1.52 | ₹1.41 |
Board & Governance of Vaishali Pharma Limited
As per the corporate governance filing with NSE for the quarter ended 31-MAR-2026, the board of Vaishali Pharma Limited has 6 directors - 3 independent and 3 executive. The board is chaired by ATUL ARVIND VASANI.
| Director | Position | On board since | Listed boards |
|---|---|---|---|
| ATUL ARVIND VASANI | Executive Director · MD · Chairperson | 2008-04-25 | 1 |
| JAGRUTI ATUL VASANI | Executive Director | 2009-11-12 | 1 |
| DEWANSH AJAY VASANI | Executive Director | 2018-04-26 | 1 |
| MANISH BHAGWANDAS VED | Non-Executive - Independent Director | 2019-12-31 | 1 |
| PRATIK VIKRAM JAKHELIA | Non-Executive - Independent Director | 2021-07-10 | 1 |
| BHAVESHKUMAR POPATLAL UPADHYAY | Non-Executive - Independent Director | 2025-01-28 | 1 |
| Committee | Members |
|---|---|
| Audit Committee | ATUL ARVIND VASANI, MANISH BHAGWANDAS VED (Chairperson), PRATIK VIKRAM JAKHELIA, BHAVESHKUMAR POPATLAL UPADHYAY |
| Nomination and remuneration committee | MANISH BHAGWANDAS VED (Chairperson), PRATIK VIKRAM JAKHELIA, BHAVESHKUMAR POPATLAL UPADHYAY |
| Stakeholders Relationship Committee | MANISH BHAGWANDAS VED (Chairperson), PRATIK VIKRAM JAKHELIA, DEWANSH AJAY VASANI, BHAVESHKUMAR POPATLAL UPADHYAY |
Charges & Borrowings of Vaishali Pharma Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 16 May 2025 | Others | ₹9.99 Lakh | Open |
| 29 Mar 2025 | Yes Bank Limited | ₹4.23 Cr | Open |
| 30 Sep 2020 | Others | ₹26 Lakh | Open |
| 05 Jan 2019 | Others | ₹3 Cr | Open |
| 31 Jan 2015 | L&T Housing Finance Limited | ₹1.75 Cr | Open |
Total charge records: 13 View all charges
Employees and EPFO Compliance at Vaishali Pharma Limited
View historical data on people associated with Vaishali Pharma Limited, including employment history and EPFO contributions.
Employee and EPFO history for Vaishali Pharma Limited
Monthly headcount, contribution history, establishment records, and filing compliance require an active report plan.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
GST Compliance of Vaishali Pharma Limited
GST registrations and filing compliance for Vaishali Pharma Limited
State-wise registrations, return filing status, HSN and SAC details, and jurisdiction records require an active report plan.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
Credit Ratings, Litigation & Regulatory Alerts for Vaishali Pharma Limited
Credit ratings, litigation, and regulatory alerts for Vaishali Pharma Limited
Agency ratings, court records, regulatory events, and entity-specific compliance alerts require an active report plan.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Vaishali Pharma Limited
MSME payment history for Vaishali Pharma Limited
Amounts outstanding to micro and small suppliers, delay reasons, and MSME-1 filing history require an active report plan.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Vaishali Pharma Limited
Corporate group structure for Vaishali Pharma Limited
Parent, subsidiary, associate, joint venture, and ownership records require an active report plan.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Vaishali Pharma Limited
MCA filings and documents for Vaishali Pharma Limited
Official forms, annual returns, financial statements, charge filings, and document dates require an active report plan.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Recent Activity on Vaishali Pharma Limited
Recent News on Vaishali Pharma Limited
Frequently Asked Questions about Vaishali Pharma Limited
Vaishali Pharma Limited is an active public limited company in the pharma sector based in Mumbai, Maharashtra, India. It was incorporated on 25 April 2008 (18+ years old) and is registered under CIN L52310MH2008PLC181632. Listed on NSE: VAISHALI. The company has 15 employees.
Vaishali Pharma Limited reported revenue of ₹108.77 Cr for FY 2026 based on consolidated NSE filings.
The current directors of Vaishali Pharma Limited are:
- Atul Arvind Vasani - Managing Director
- Jagruti Atul Vasani - Whole-Time Director
- Dewansh Ajay Vasani - Director
- Manish Bhagwandas Ved - Director
- Pratik Vikram Jakhelia - Director
- Bhaveshkumar Popatlal Upadhyay - Director
The primary industry of Vaishali Pharma Limited is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.
Yes. Vaishali Pharma Limited is listed on NSE with symbol VAISHALI.
Vaishali Pharma Limited can be reached at the registered office: 706 To 709 7Th Fl Aravali Busines Center R. C. Patel Road Off Sodawala Lane Bor, Ivali West, Mumbai, Maharashtra, India – 400092, or through the website vaishalipharma.com.